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Abstract The Ras proteins cycle in the cell between an inactive
state and an active state. In the active state, Ras signals via the
switch I region to effectors like c-Raf kinase, leading to cell
growth. Since Ras mutations in cancer are often associated with
the presence of permanently active Ras, molecules that prevent
downstream signaling may be of interest. Here, we show that by
selection on the active conformation of Ras, using a recently
described large phage antibody repertoire [de Haard et al. (1999)
J. Biol. Chem. 274, 18218^18230], a Fab antibody (Fab H2) was
identified that exclusively binds to active Ras, and not to inactive
Ras. Using surface plasmon resonance (SPR) analysis, the
interaction was demonstrated to be of high affinity (7.2 nM). In
addition, the interaction with Ras is specific, since binding to the
homologous Rap1A protein in BIAcore analysis is at least three
orders of magnitude lower, and undetectable in an enzyme-linked
immunosorbent assay. The antibody fragment prevents the
binding of active Ras to the immobilized Ras-binding domain
of c-Raf kinase (Raf-RBD) at an IC50 value of 135 nM. This
value compares well to the KD of active Ras-binding to
immobilized Raf-RBD using SPR, suggesting identical binding
sites. Like the IgG Y13-259, which does not demonstrate
preferential binding to either inactive or active Ras, Fab H2
inhibits intrinsic GTPase activity of Ras in vitro. Mapping
studies using SPR analysis demonstrate that the binding sites for
the antibodies are non-identical. This antibody could be used for
dissecting functional differences between Ras effectors. Due to
its specificity for active Ras, Fab H2 may well be more selective
than previously used anti-Ras antibodies, and thus could be used
for gene therapy of cancer with intracellular antibodies.
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1. Introduction
The Ras proteins are guanine nucleotide binding molecules,
essential for normal cellular proliferation and di¡erentiation
[1,2]. These proteins belong to a superfamily of proteins
termed GTPases that cycle between on and o¡ states triggered
by binding and hydrolysis of the guanosine triphosphate
(GTP) nucleotide [3,4]. Because of the ability to bind to di¡er-
ent guanine nucleotides, leading to structural changes in the
molecule, Ras serves as a molecular switch in signal trans-
duction pathways [5,6]. The importance of Ras in normal
cell physiology is underscored by the fact that in many types
of human cancer the protein is mutated. In particular, onco-
genic mutations are found in both glutamine 61 and glycine
12 [7]. Such mutations a¡ect the intrinsic GTPase activity of
Ras, rendering the molecule to be trapped in the active form
[8]. The oncogenic Ras species resemble the active form of
Ras on a biochemical as well as on a structural level [9,10],
however, structural di¡erences account for the loss of inacti-
vation in mutated Ras by the GTPase activating protein
p120GAP [11].
Crystal structures of the catalytic sites of both the active
and inactive forms of Ras in complex with nucleotides have
been determined as well as the structures of nucleotide bound
Ras [10,12^16]. These studies have demonstrated that the
switch I (residues 30^37) and switch II (residues 60^76) re-
gions of Ras are conformationally a¡ected by exchange of the
guanine nucleotides. Particularly switch I appears to be in-
volved in the functional activity of Ras, since this domain
overlaps the region generally referred to as the e¡ector loop
(residues 32^40) [17,18]. The e¡ectors of Ras, amongst others
c-Raf kinase, function as downstream signal transducing mol-
ecules, which only bind to the active form of Ras.
Extensive studies on the interaction of Raf-1 with Ras have
demonstrated that on Raf-1 the binding residues are located
within residues 55^131, generally referred to as Raf-RBD (Ras
binding domain) [19]). The a⁄nity of Raf-RBD for GTP-Ras
has been determined to be 18 nM, whereas the a⁄nity for
guanosine diphosphate- (GDP)-Ras was shown to be in the
micromolar range [20]. Determination of the crystal structure
of the complex of the Ras-related protein Rap1A in the active
form and Raf-RBD and by inference that of the complex of
Ras with Raf-RBD has provided detailed insight into the
switch I residues involved in the interaction [21]. Since it has
been suggested that oncogenic Ras is insensitive to GAP ac-
tivity, targeting the binding site of the e¡ectors may be an
option to obtain reagents to treat Ras induced tumors [22].
The e¡ector binding site has been suggested to be highly anti-
genic, based on peptide studies, and therefore may be a suit-
able target to select antibodies against Ras [23].
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The neutralizing monoclonal antibody Y13-259 has been
shown to inhibit the GTPase activity of Ras, binding to res-
idues constituting the switch II region [24,25]. In vitro, the
antibody either sterically hinders the interactions of e¡ector
molecules binding to switch I, or prevents the exchange of
GDP for GTP by compromising the conformational £exibility
of Ras [26]. In vivo, the antibody has been demonstrated to
inhibit Ras-mediated pathways using microinjection assays
[27]. The variable domains of heavy and light chains of
Y13-259 have been expressed as single chain Fv fragment
(scFv) inside eukaryotic cells [28,29] (a technology generally
referred to as intracellular immunization or intrabody expres-
sion, [30,31]). Upon intracellular expression, the scFv Y13-259
inhibits transforming activity in a number of studies [32,33],
and even speci¢cally induces apoptosis in human cancer cells
but not in untransformed cells [34]. Nevertheless, the Y13-259
monoclonal antibody has been shown to be largely insoluble
when expressed at 37‡C cells, leading to intracellular aggrega-
tion [35].
Phage display technology has been demonstrated to allow
for rapid selection of human antibodies from large repertoires
to any protein of interest (for a recent review, see [36]). Persic
et al. used this approach to obtain human antibody scFv
fragments to the switch II region of Ras using a peptide rep-
resenting this domain for selection [37]. Anti-Ras antibodies
were isolated, many of which were shown to inhibit cellular
functions in mammalian cells (unpublished). In this study, we
attempted to derive antibodies towards epitopes which are
conformationally changed upon exchange of nucleotides, in
particular the e¡ector loop, using the recently constructed
large non-immunized phage-displayed antigen binding frag-
ment (Fab) antibody repertoire [38]. We report here the iso-
lation of a panel of human antibodies to Ras, some of which
could be used either for dissecting the role of Ras-e¡ector
interactions in cell physiology or eventually for cancer gene
therapy, using intracellularly expressed antibodies.
2. Materials and methods
2.1. Proteins and chemicals
Glutathione S-transferase fused H-Ras (GST-Ras), the catalytic
fragment of p120Gap (GAP334) and the Raf-RBD were puri¢ed as
described [11,20,39,40]. The monoclonal IgG antibodies Y13-259
and F111-85 were purchased from Oncogene Sciences and polyclonal
goat anti-GST as well as the pGEX4T2 vector were from Amersham
Pharmacia Biotech. GST, encoded by the latter vector, was puri¢ed
after expression in E. coli strain TG1 and subsequent puri¢cation
using glutathione beads, according to the instructions of the supplier.
Guanine thiotriphosphate (GTPQS) was purchased from Boehringer
Mannheim. All other reagents and chemicals used were reagent grade
(Sigma or Merck).
2.2. Selections on conformationally restricted Ras
Immunotubes (NUNC) were coated overnight at 4‡C with 100 Wg
anti-GST. After washing three times with 20 mM Tris containing 150
mM NaCl, pH 7.4 (TBS), tubes were blocked with TBS containing 2%
w/v skimmed milk powder for 1 h at 37‡C. 1 WM GST-Ras was ¢rst
bound to GDP or GTPQS by incubation in TBS containing 1 mM
EDTA and the relevant nucleotide for 20 min at 37‡, followed by
addition of 5 mM MgCl2. Subsequently, GST-Ras was captured by
coated anti-GST for 30 min at 37‡C. Unbound GST-Ras was re-
moved by performing three washing steps with TBS. Prior to selection
on GST-Ras, 2U1012 phage from the non-immunized Fab repertoire
[38], was depleted on coated goat serum for 30 min at 37‡C. Unbound
phage was suspended into TBS containing 2% marvel, and allowed to
bind for 90 min at room temperature to the captured GST-Ras. Sub-
sequently, tubes were washed extensively using TBS with and without
0.1% Tween 20 and bound phage was eluted using glycine-adjusted 50
mM hydrochloric acid, pH 2.0. Phages were rescued and ampli¢ed as
described [41], followed by another two rounds of selections. Phage
repertoires were alternately depleted either by preincubation on
coated goat serum or by adding 25% goat serum to the incubation
mixture during the selection. During the third round of selection, the
library was also depleted on anti-GST captured GST, prior to selec-
tion on GST-Ras.
2.3. Screening of the selected anti-GDP/GTPQS-Ras repertoires
To identify GDP or GTPQS-Ras binding clones, an enzyme-linked
immunosorbent assay (ELISA) was performed in which GST-Ras,
after treatment with the relevant nucleotides, was captured by poly-
clonal anti-GST. Coated wells were blocked using TBS containing 3%
w/v bovine serum albumin and Fab-phage expressed by single colonies
were allowed to bind for 1 h at room temperature. Subsequent ELISA
washing and staining procedures were essentially as described [42].
The number of unique Fabs was determined by PCR ¢ngerprinting
using BstNI as described [41] followed by DNA sequencing.
2.4. Puri¢cation of Fab fragments and surface plasmon resonance
a⁄nity measurements
Selected anti-Ras Fab fragments were expressed upon induction
with isopropyl-L-D-thiogalactopyranoside (IPTG), harvested from
the periplasmic space of E. coli TG1 cells and puri¢ed by immobilized
metal a⁄nity chromatography. Brie£y, IPTG induced 500 ml cultures
(4 h at 30‡C), expressing relevant anti-Ras antibodies, were spun at
4600Ug for 20 min at 4‡C. Bacteria were subsequently resuspended in
phosphate bu¡ered saline containing protease inhibitors (phenyl-
methyl-sulfonyl £uoride and benzamidine) and sonicated using an
ultrasonic disintegrator (MSE Scienti¢c Instruments). Suspensions
were then centrifuged at 50 000Ug for 30 min at 4‡C, and supernatant
fractions were incubated with TALON resin and eluted from the
beads according to the instructions of the manufacturer (Clontech).
Fab fragments were further puri¢ed by gel ¢ltration using a Superdex
75 column (Amersham Pharmacia Biotech) connected to a Biologic
instrument (Bio-Rad). Fab concentrations were quantitated using the
bicinchoninic acid kit (Pierce).
To determine equilibrium dissociation constants, anti-GST anti-
bodies were immobilized onto a CM5 sensorchip in a BIAcore2000
instrument (Biacore AB) by amine coupling at a high density of 120^
140 fmol/mm2. Using TBS containing 2 mM MgCl2 and 0.01% v/v
Tween 20 as a running bu¡er, the anti-GST was either loaded with
GST or GST-Ras bound to GDP, GTP or GTPQS at a £ow rate of
5 Wl/min at 25‡C, resulting in approximately 15 fmol captured protein,
allowing for proper kinetic determinations. After increasing the £ow
rate to 20 Wl/min, Fab antibodies were passed over the sensorchip at
multiple concentrations around apparent KD values. Binding to either
GST or anti-GST was subtracted from speci¢c binding responses to
Ras. The rate constants kon and koff were obtained by direct ¢tting
and from secondary plots (ks versus concentration), respectively, and
¢tted to the data according to a single-site model, using the BIAeval-
uation 2.1 software (Biacore AB). KD values that were calculated from
kon and koff rate constants, ful¢lled the criteria for self-consistency
[43].
2.5. Competition studies using surface plasmon resonance analysis
Raf-RBD was immobilized onto a CM5 sensorchip (Biacore AB)
up to approximately 4500 resonance units (RU; corresponding to 4.5
ng of protein). Prior to the analyses, Ras was loaded with GDP, GTP
or GTPQS as described above. Using TBS containing 0.01% v/v Tween
20 and 2 mM MgCl2 as running bu¡er using £ow conditions of 10 Wl/
min, 100 nM of GTPQS loaded Ras, either untreated or preincubated
with 1 WM concentrations of relevant antibodies, was passed over
multiple Raf-RBD immobilized channels and residual binding was
measured after 2 min association time. Fab antibodies were incubated
over a range of concentrations. In case of no inhibition of Ras bind-
ing, results are indicated in the ¢gure as 100% residual binding at the
highest tested concentration.
2.6. GTPase assays
Hydrolytic activity of Ras either in the presence or absence of
competitors was determined by performing GTPase assays according
to the charcoal method of Bollag and McCormick [44]. In these ex-
periments, Ras was incubated either in the presence or absence of the
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anti-Ras antibodies Fab H2, Fab A8 or IgG Y13-259 and GAP334 at
concentrations of 1 WM. Experiments were performed in duplicate.
2.7. Mapping studies
Mapping studies using surface plasmon resonance analysis (SPR)
were performed by loading the anti-GST immobilized chip with 8.3
fmol (400 RU) of Ras-GTP, followed by injections well over KD of
IgG Y13-259 immediately followed by saturating amounts of Fab H2.
First, saturating amounts of either antibody was determined to be
maximally 150 RU for IgG Y13-259 and 350 RU for Fab H2, re-
spectively. Next, in the actual experiment, responses obtained were
compared to these values.
3. Results
3.1. Selections of Fab antibodies on active and inactive
GST-Ras
Phage antibodies against Ras from large phage single chain
Fv antibody libraries have been selected previously by a num-
ber of methods, either selecting on peptides representing func-
tional epitopes [37], or selecting on the full-length protein
(unpublished results). However, to our knowledge antibodies
have never been identi¢ed speci¢c for the conformational state
of Ras, neither by hybridoma nor phage antibody technology.
Since it has been suggested in literature [23] that particularly
residues in the switch I region of the protein may be highly
antigenic and that these residues appear to be either exposed
or cryptic upon conformational changes induced by guanine
nucleotide exchange, we have set out to identify antibodies
with exquisite speci¢city by selection on GDP or GTP bound
Ras. GTP speci¢c antibodies may later be used for intracel-
lular immunization, in order to block Ras function in tumor
cells. In addition, selection on conformational Ras and isola-
tion may serve as a paradigm for the superfamily of GTP-
binding proteins, the members of which are considerably ho-
mologous and, most importantly, contain switch regions de-
termining the speci¢city for intracellular e¡ector molecules
[45].
We chose to select antibodies to GST-Ras from the
37 000 000 000 clones Fab antibody library, that has recently
been constructed in our laboratory [38]. Ras was not immo-
bilized to prevent immobilization-induced conformational
changes but was captured by antibodies directed to the GST
moiety. By selection on GDP or GTPQS GST-Ras, while ex-
tensively depleting for GST binders and binders speci¢c for
anti-GST antibodies as described in Section 2, we obtained a
panel of Fab fragments binding to Ras. During the four con-
secutive rounds of selection, we found an increase in the ratios
of output phage over input, indicative of enrichment for anti-
gen binders, mounting to three orders of magnitude for both
selections on GDP and GTPQS GST-Ras. To demonstrate
binding of individual Ras Fabs, we performed a phage ELI-
SA, in which we captured GST-Ras either bound to GDP or
GTP. From both pannings, after the third round of selection,
we obtained anti-Ras binders as indicated by this ELISA (70^
80% positives, data not shown). To be able to demonstrate
speci¢city for a de¢ned Ras conformation, we next performed
an ELISA, in which we either captured GDP-Ras, GTP-Ras,
GST or no protein at all, and bound phage antibodies were
detected. The results are shown in Fig. 1. From both selec-
tions, Fabs were selected binding to either form of Ras. The
Fabs A3, A8, A11, A12, B4 and G2 were all obtained from
the GDP-Ras selections. The Fabs A4, C6, C7, H2 and H3
were derived from the GTP-Ras selections. The selections also
yielded a low percentage (6 10%) non-speci¢c binders and
GST binders. As can be seen in Fig. 1, Fab H2 demonstrated
speci¢city for the active conformation of Ras. During the
selections on GTP-Ras without depleting on captured GST,
anti-GTP-Ras binders (Fab H2) were dominantly enriched
(48.9% of binding Fabs). By depletion on GST, this number
increased to 75% (see also Table 1). The percentage of GST
binders (e.g. Fab H3) was reduced concomitantly from 40 to
5.5%. Selections on GDP-Ras yielded Ras binders which do
not discriminate between active and inactive Ras. Using
BstNI ¢ngerprinting and DNA sequencing, we could identify
nine di¡erent anti-Ras clones.
Fig. 1. Phage ELISA screening of Ras selected Fab phage. Binding
to GTPQS-Ras is indicated by the black bars, binding to GDP-Ras
by the hatched bars and binding to either captured GST or anti-
GST by the dotted and open bars, respectively. A3, A8, A11, A12,
B4 and G2 Fab phage were all selected on GDP-Ras, whereas A4,
C6, C7, H2 and H3 were derived from GTPQS-Ras selections. Y13
refers to the cloned Y13-259 scFv form [28].
Table 1
GST depletion prior to pannings on GST-GTPQS-Ras increases the
number of Ras-speci¢c clones after three rounds of selection





Fig. 2. Binding of Fab H2 and Fab A8 to captured GTP- or GDP-
Ras using SPR. A: Dose-dependent binding of Fab H2 to captured
Ras. The ¢gure shows initial loading of anti-GST with GST-Ras, ei-
ther bound to GTP (1) or GDP (2), and subsequent binding of the
antibody. B and C: Dose-dependent binding of Fab A8 to captured
Ras, either to GTP- or GDP-Ras, respectively.
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3.2. A⁄nity determination of anti-Ras Fab antibodies
Next, we puri¢ed the Fab antibodies H2 (active Ras specif-
ic), A8 and A11 (both pan-Ras reactive) as three representa-
tive clones and determined the a⁄nity of the clones for Ras
using SPR. To compare binding to di¡erent Ras-forms, we
developed a BIAcore assay as follows. After coupling a high
amount of polyclonal anti-GST to a CM5 BIAcore sensor-
chip, we captured Ras either treated with GDP or GTPQS and
subsequently measured the interaction of the antibodies with
the captured Ras. Fig. 2 shows two sensorgrams run synchro-
nously in di¡erent channels. In channel 1, a low amount of
GTPQS-Ras and in channel 2 a low amount of GDP-Ras was
captured. After capturing per channel individually at a £ow
rate of 5 Wl/min, £ow rates were increased to 20 Wl/min to
allow for kinetic determinations and antibodies were passed
synchronically over both channels and a control background
channel. As can be seen in Fig. 2A, Fab H2 only binds to the
active form of Ras. The calculated Kd for the interaction is 7.2
nM (ka, 3.6U105 M31 s31, kd, 2.6U1033 s31). The speci¢city
for Ras was demonstrated by the fact that Fab H2 does not
interact with the related Rap1A protein (not shown). The Kd
value of the interaction of Fab H2 with active Ras compares
well to a calculated Kd value determined in an ELISA (6 nM,
data not shown). Fab A8 bound to both forms of Ras
(GTPQS-Ras, Fig. 2B and GDP-Ras, Fig. 2C), although
with lower a⁄nity (calculated Kd values 197 nM and 211
nM for GTPQS-Ras and GDP-Ras, respectively). The interac-
tion of A11 with Ras was not quantitated accurately, how-
ever, the apparent a⁄nity was in the same order of magnitude
as that of Fab A8. The reverse experiment, in which the anti-
bodies Fab H2 and A8 were immobilized to CM5 sensorchips
and subsequent binding of either GDP, GTP or GTPQS-Ras
was measured, yielded similar results (data not shown).
3.3. Competition of Fab antibodies for Ras binding to
Raf-RBD
Recently, using SPR, we measured binding of GTPQS-Ras
and GTP-Ras, but not GDP-Ras to immobilized Raf-RBD
and determined possible interference of selected scFv’s on this
interaction (unpublished results). None of the tested antibod-
ies, selected on directly coated Ras, were capable of inhibition.
Only Y13-259, either in the IgG or scFv format, was capable
of completely inhibiting the binding at micromolar concentra-
tions. We used the same experimental setup to determine if
our newly selected antibodies, directed to conformational epit-
opes, may interfere with the Ras-Raf-RBD interaction. As
shown in Fig. 3, the Fab H2 antibody inhibits the interaction
in a dose-dependent fashion, at an IC50 value of 135 nM. The
obtained BIAcore curves are shown in the inset ¢gure. A
control antibody which demonstrates a good a⁄nity for Ras
(anti-Ras 3, KD 52 nM, unpublished), as well as the Fab A11
did not inhibit the interaction up to micromolar concentra-
tions. Because of the observed inhibition of GTPQS-Ras bind-
ing to Raf-RBD by Fab H2, we compared the DNA encoding
VH and VL regions of Fab H2, with the primary sequence of
Raf-RBD, but were unable to ¢nd similarities or signi¢cant
homologies (data not shown).
3.4. GTPase assays
Since the IgG Y13-259 antibody can inhibit Ras mediated
signal transduction in in vivo assays, preventing GTPase ac-
tivity in in vitro systems and interacting with the conforma-
tionally £exible switch II region, we were curious to see if the
H2 antibody could also exert GTPase inhibitory activity.
Therefore, we performed standard GTPase assays as described
by Bollag and McCormick [44]. As controls, we performed
incubations with Y13-259, either in the IgG or scFv format,
with irrelevant antibodies (anti-MHC Fab G8, Cha“mes et al.,
unpublished) and with GAP334. As expected, the incubations
with irrelevant antibodies did not in£uence the rate of intrin-
sic GTPase activity, whereas the incubations with Y13-259 or
GAP334 completely inhibited or strongly stimulated the ac-
tivity, respectively (Fig. 4). Upon incubation with Fab H2, the
GTPase activity of Ras was completely blocked. scFv anti-
Ras antibodies directed to regions which are una¡ected by
conformational changes did neither inhibit nor stimulate
GTPase activity (unpublished results).
3.5. Mapping study
Because of comparable features of antibody Y13-259 and
Fab H2, we performed a mapping study using SPR. In this
assay, we captured GTPQS-Ras with anti-GST and subse-
Fig. 4. GTPase assay. Triangles (R) indicate the hydrolysis of Ras
either in the presence or absence of irrelevant (G8) or anti-Ras Fab
A11 antibodies. In£uences on the GTPase activity by GAP-334 and
by IgG Y13-259 are represented by the diamonds (8) and by the
circles (b), respectively. Incubations in the presence of Fab H2 are
represented by the squares (F).
Fig. 3. BIAcore competition experiment. Measurements of competi-
tion of Ras binding to Raf-RBD by scFv anti-Ras 3 (R), Fab A11
(F), or Fab H2 (b), using SPR. The binding curves, representing
Ras binding in the absence of Fab H2 (upper curve), or increasing
amounts up to 1 WM (lower curve), are shown in the inset ¢gure.
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quently determined maximal binding responses of antibodies
binding to Ras. Taking into account the molecular mass of
the antibody, maximal binding of Y13-259 was lower than
expected, possibly due to a low accessibility of the epitope
in this experimental setup. After determining the maximal
binding responses, we saturated the Ras with IgG Y13-259
and then injected a saturating amount of Fab H2. The results
of this experiment are depicted in Fig. 5. As can be deduced
from this ¢gure, Y13-259 and Fab H2 can both bind to the
captured Ras, indicative of independent binding sites. The
opposite experiment, in which Ras was ¢rst saturated with
Fab H2 and then with Y13-259, yielded similar results. Be-
cause of the apparent low accessibility of the Y13-259 epitope
in the SPR assay, we performed a competitive ELISA in
which we competed with Y13-259 for Fab H2 binding and
reverse under conditions of half-maximal saturation. Since
competition was observed only at high concentrations of
Y13-259 for Fab H2 binding, whereas the reverse could not
be shown, we conclude that the binding sites are non-identi-
cal.
4. Discussion
In the present study, we have used phage display technol-
ogy to rapidly select antibodies to the active conformation of
Ras. In this way, we attempted to increase the chance of
isolating antibodies capable of inhibiting the interaction of
downstream e¡ectors like c-Raf kinase with Ras. We have
used a large Fab antibody library, which in our lab has
yielded a number of antibodies to diverse antigens binding
to their targets with nanomolar a⁄nities [38]. This library
was selected on captured GST-Ras, bound to either GDP or
GTPQS. This approach yielded a Fab antibody that interacts
with Ras with high a⁄nity and inhibits the intrinsic GTPase
activity and the binding of Ras to Raf-RBD. Surprisingly, the
selections on GDP-Ras did not yield any clones speci¢c for
the inactive conformation. In fact, several antibodies were
obtained that interact with Ras irrespective of the conforma-
tional state. The reason for these ¢ndings may be the fact that
the e¡ector loop is highly £exible in the GDP-bound state, but
rather ¢xed in the GTP-bound state, when it exists in only
two conformations due to the fact that the Q-phosphate inter-
acts with a tyrosine residue in the loop [46]. It also suggests
that the e¡ector binding domain, to which Fab H2 seems to
bind, only contains selection dominant epitopes in the active
conformation. The latter suggestion is strengthened by the
fact that in addition to a panel of Ras binders, the GTP-
Ras speci¢c H2 clone was dominantly selected (see also Table
1) and the a⁄nities of antibodies to Ras indi¡erent of the
conformation, were rather low (1037 M). Studies undertaken
by Wang and colleagues, who made Ras peptides and isolated
antibodies against them, have indicated that particularly the
e¡ector binding region may be highly antigenic in vivo [23].
Selection-dominant epitopes may often be overlapping with
immunogenic epitopes, as demonstrated in a study by Hoo-
genboom et al. [47]. The possible immunogenicity of the ef-
fector loop may as well explain the strong selection of the high
a⁄nity Fab H2 during the stringent selections.
Since members of the superfamily of GTP-binding proteins
are all characterized by the presence of the switch regions,
which are a¡ected conformationally upon nucleotide binding,
the method described could well serve as a general way to
rapidly select antibodies against these conformationally £exi-
ble regions. Particularly, if the aim would be to discriminate
between di¡erent GTP-binding proteins, mediating di¡erent
cellular events by binding to di¡erent e¡ectors, this method
may be applicable, since the Fab H2 antibody demonstrates a
much higher a⁄nity for Ras than for Rap1A. The di¡erence
in a⁄nity is at least three orders of magnitude in BIAcore,
and binding of Fab H2 to Rap1A in ELISA could not be
detected at all.
The Fab H2 antibody could be an interesting candidate for
intracellular antibody expression studies. Work is currently
performed to clone the antibody in a suitable eukaryotic ex-
pression vector [29] and express it in the smaller scFv format.
Antibodies have been intracellularly expressed in a number of
studies [30,31]. However, attempts to express antibodies that
were obtained by classical hybridoma technology and subse-
quently cloned have not always been successful. The antibody
may not fold correctly in certain compartments of eukaryotic
cells and expression levels may be poor. This may be corrected
by mutation and selection as was proposed by Martineau et
al. for cytoplasmic antibody expression inside bacteria [48].
On the other hand, a new mechanism of action may be ob-
served upon intracellular expression of an antibody in a di¡er-
ent molecular format. This was proven to be the case for the
Y13-259 antibody by Cardinale and co-workers when they
expressed the scFv format of this antibody in a eukaryotic
cell system [35]. The scFv was highly aggregating intracellu-
larly, thereby trapping the intracellular Ras in an insoluble
complex which can be subsequently degraded by the cell.
The question remains if a targeted approach is actually
required for inactivation of intracellular targets. In a recent
study, Lener and coworkers have shown that expression of
non-inhibitory antibodies intracellularly may very well lead
to aggregation resulting in inhibition of intracellular functions
or pathways (unpublished). In this study, the measured low
a⁄nity did not appear to a¡ect the e⁄ciency of intracellular
target inactivation. The Fab H2 antibody, however, demon-
strates speci¢city for Ras and can inhibit a particular protein-
protein interaction, thereby most likely allowing us to discrim-
inate between inhibition of certain intracellular pathways. Be-
cause of its speci¢city, it may also be used to quantitate intra-
cellular active Ras levels. Alternatively, molecules (either
antibodies or alternative sca¡olds) inhibiting particular intra-
cellular interactions or signal transduction routes, could also
Fig. 5. Epitope mapping of Fab H2 binding to Ras using SPR.
Captured GTPQS-Ras was ¢rst saturated with monoclonal antibody
Y13-259 and subsequently incubated with Fab H2.
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be selected using an in vivo approach. Screening could sub-
sequently be performed based on for instance phenotypic
changes, apoptosis, cell morphology or surface protein expres-
sion. The initial proof of concept of an in vivo approach has
been reported by Gargano and Cattaneo in a study in which
cells expressing anti-retroviral antibodies were rescued [49].
An in vivo selection may be done using a previously selected
antibody repertoire, directed against a known antigen, as well
as using a completely naive repertoire. In the latter case, the
unknown target will be identi¢ed in a later instance, possibly
yielding new insights in importance of molecules involved in
signal transduction pathways or leading to the discovery of
new signal transduction molecules. Such antibodies will per
de¢nition be antibodies that can be expressed intracellularly,
avoiding the possible problems associated with expression of
in vitro selected antibodies. Well expressed antibodies, for
example selected for high level expression inside the cell using
procedures as described by Martineau, may later be used as a
sca¡old to create new libraries [48]. We conclude that high
a⁄nity antibodies directed to the active conformation of Ras
can rapidly be selected from large phage-displayed antibody
libraries. As shown in this paper, binding of the antibodies to
conformational epitopes is very likely to be associated with
functional inhibition of e¡ector binding, since interaction of
such molecules is governed by the conformational state of
Ras. We propose this method to be generally applicable for
selection of antibodies to conformational regions in related
GTP-binding proteins.
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